The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis

Janet E Olson, Carol A. Janney, Ravi D. Rao, James R Cerhan, Paul J. Kurtin, David Schiff, Richard S. Kaplan, Brian Patrick O'Neill

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

BACKGROUND. Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears to be increasing. METHODS. PCNSL incidence data from 1973-1997 were obtained from the nine Surveillance, Epidemiology and End Results (SEER) registries. To limit the influence of the human immunodeficiency virus on incidence rates, data of never-married males and females and persons of unknown marital status were excluded. As a surrogate for new technology, SEER data were reviewed by dates of diagnosis (surrogate for imaging) and compared with glioma incidence (surrogate for stereotactic neurosurgery and improved diagnostic neuropathology). Age-adjusted incidence rates were estimated and compared for the period prior to computed tomography (CT) (1973-1984) and the magnetic resonance imaging (MRI) period (1985-1997). The estimated annual percent change was calculated based on linear regression analyses using SEER*STAT. RESULTS. The incidence of PCNSL appears to be increasing in all SEER registries examined. All age groups demonstrated an increase over time. This increase was observed both in the CT era as well as in the MRI era. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the same registries over the same time periods. The rate of increase has begun to slow since 1985; the estimated annual percent change for PCNSL was three-fold higher during the period 1973-1985 compared with 1986-1997. CONCLUSION. The incidence rate of PCNSL continues to rise. The increase is evident in all age groups and in both genders. Data from the current study suggest that improved diagnostic tools, such as CT or MRI, cannot explain this increase.

Original languageEnglish (US)
Pages (from-to)1504-1510
Number of pages7
JournalCancer
Volume95
Issue number7
DOIs
StatePublished - Oct 1 2002

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Epidemiology
Central Nervous System
Incidence
Registries
Tomography
Magnetic Resonance Imaging
Age Groups
Marital Status
Neurosurgery
Glioma
Linear Models
Regression Analysis
HIV
Technology

Keywords

  • And End Results (SEER) program
  • Brain tumor
  • Epidemiology
  • Lymphoma
  • Primary central nervous system lymphoma (PCNSL)
  • Surveillance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma : A surveillance, epidemiology, and end results analysis. / Olson, Janet E; Janney, Carol A.; Rao, Ravi D.; Cerhan, James R; Kurtin, Paul J.; Schiff, David; Kaplan, Richard S.; O'Neill, Brian Patrick.

In: Cancer, Vol. 95, No. 7, 01.10.2002, p. 1504-1510.

Research output: Contribution to journalArticle

@article{bb3e7f51955a40b4b9b186cfe00da8a2,
title = "The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis",
abstract = "BACKGROUND. Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears to be increasing. METHODS. PCNSL incidence data from 1973-1997 were obtained from the nine Surveillance, Epidemiology and End Results (SEER) registries. To limit the influence of the human immunodeficiency virus on incidence rates, data of never-married males and females and persons of unknown marital status were excluded. As a surrogate for new technology, SEER data were reviewed by dates of diagnosis (surrogate for imaging) and compared with glioma incidence (surrogate for stereotactic neurosurgery and improved diagnostic neuropathology). Age-adjusted incidence rates were estimated and compared for the period prior to computed tomography (CT) (1973-1984) and the magnetic resonance imaging (MRI) period (1985-1997). The estimated annual percent change was calculated based on linear regression analyses using SEER*STAT. RESULTS. The incidence of PCNSL appears to be increasing in all SEER registries examined. All age groups demonstrated an increase over time. This increase was observed both in the CT era as well as in the MRI era. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33{\%} increase) for the same registries over the same time periods. The rate of increase has begun to slow since 1985; the estimated annual percent change for PCNSL was three-fold higher during the period 1973-1985 compared with 1986-1997. CONCLUSION. The incidence rate of PCNSL continues to rise. The increase is evident in all age groups and in both genders. Data from the current study suggest that improved diagnostic tools, such as CT or MRI, cannot explain this increase.",
keywords = "And End Results (SEER) program, Brain tumor, Epidemiology, Lymphoma, Primary central nervous system lymphoma (PCNSL), Surveillance",
author = "Olson, {Janet E} and Janney, {Carol A.} and Rao, {Ravi D.} and Cerhan, {James R} and Kurtin, {Paul J.} and David Schiff and Kaplan, {Richard S.} and O'Neill, {Brian Patrick}",
year = "2002",
month = "10",
day = "1",
doi = "10.1002/cncr.10851",
language = "English (US)",
volume = "95",
pages = "1504--1510",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma

T2 - A surveillance, epidemiology, and end results analysis

AU - Olson, Janet E

AU - Janney, Carol A.

AU - Rao, Ravi D.

AU - Cerhan, James R

AU - Kurtin, Paul J.

AU - Schiff, David

AU - Kaplan, Richard S.

AU - O'Neill, Brian Patrick

PY - 2002/10/1

Y1 - 2002/10/1

N2 - BACKGROUND. Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears to be increasing. METHODS. PCNSL incidence data from 1973-1997 were obtained from the nine Surveillance, Epidemiology and End Results (SEER) registries. To limit the influence of the human immunodeficiency virus on incidence rates, data of never-married males and females and persons of unknown marital status were excluded. As a surrogate for new technology, SEER data were reviewed by dates of diagnosis (surrogate for imaging) and compared with glioma incidence (surrogate for stereotactic neurosurgery and improved diagnostic neuropathology). Age-adjusted incidence rates were estimated and compared for the period prior to computed tomography (CT) (1973-1984) and the magnetic resonance imaging (MRI) period (1985-1997). The estimated annual percent change was calculated based on linear regression analyses using SEER*STAT. RESULTS. The incidence of PCNSL appears to be increasing in all SEER registries examined. All age groups demonstrated an increase over time. This increase was observed both in the CT era as well as in the MRI era. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the same registries over the same time periods. The rate of increase has begun to slow since 1985; the estimated annual percent change for PCNSL was three-fold higher during the period 1973-1985 compared with 1986-1997. CONCLUSION. The incidence rate of PCNSL continues to rise. The increase is evident in all age groups and in both genders. Data from the current study suggest that improved diagnostic tools, such as CT or MRI, cannot explain this increase.

AB - BACKGROUND. Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears to be increasing. METHODS. PCNSL incidence data from 1973-1997 were obtained from the nine Surveillance, Epidemiology and End Results (SEER) registries. To limit the influence of the human immunodeficiency virus on incidence rates, data of never-married males and females and persons of unknown marital status were excluded. As a surrogate for new technology, SEER data were reviewed by dates of diagnosis (surrogate for imaging) and compared with glioma incidence (surrogate for stereotactic neurosurgery and improved diagnostic neuropathology). Age-adjusted incidence rates were estimated and compared for the period prior to computed tomography (CT) (1973-1984) and the magnetic resonance imaging (MRI) period (1985-1997). The estimated annual percent change was calculated based on linear regression analyses using SEER*STAT. RESULTS. The incidence of PCNSL appears to be increasing in all SEER registries examined. All age groups demonstrated an increase over time. This increase was observed both in the CT era as well as in the MRI era. PCNSL age-adjusted incidence (0.15 to 0.48, a 3-fold increase) outpaced that of systemic lymphoma (14.1 to 18.5, a 33% increase) for the same registries over the same time periods. The rate of increase has begun to slow since 1985; the estimated annual percent change for PCNSL was three-fold higher during the period 1973-1985 compared with 1986-1997. CONCLUSION. The incidence rate of PCNSL continues to rise. The increase is evident in all age groups and in both genders. Data from the current study suggest that improved diagnostic tools, such as CT or MRI, cannot explain this increase.

KW - And End Results (SEER) program

KW - Brain tumor

KW - Epidemiology

KW - Lymphoma

KW - Primary central nervous system lymphoma (PCNSL)

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=0036784451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036784451&partnerID=8YFLogxK

U2 - 10.1002/cncr.10851

DO - 10.1002/cncr.10851

M3 - Article

C2 - 12237919

AN - SCOPUS:0036784451

VL - 95

SP - 1504

EP - 1510

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -